ロード中...
Impact of IL-2 on Treatment Tolerance in Patients With High-Risk Neuroblastoma Treated With Dinutuximab Beta-Based Immunotherapy
Patients with high-risk neuroblastoma treated with continuous long-term infusion of anti-GD2 antibody dinutuximab beta (DB) in combination with IL-2 show an acceptable safety profile. Here, we compared treatment tolerance with and without IL-2. Ninety-nine patients with high-risk neuroblastoma recei...
保存先:
| 出版年: | Front Pediatr |
|---|---|
| 主要な著者: | , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Frontiers Media S.A.
2020
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7772209/ https://ncbi.nlm.nih.gov/pubmed/33392114 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fped.2020.582820 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|